Abstract: The present invention relates to a rapid and readily reproducible process for stabilizing biologically active substances by combining the biologically active substance witha a stabilizingmixture and drying the resulting mixture into a dry, amorphous product by means of convection drying. The invention also relates to the amorphous, microscopically homogeneous products which are obtained by this process, are in the form of powders and have a uniform geometric, in particular spherical, shape. The invention furthermore relates to the use of substance mixtures for stabilizing biologically active material, in particular proteins by means of spray drying.

Abstract: A chimeric serine protease whose protease domain is composed of two domain halves (half-sides) with a &bgr;-folded sheet structure, wherein the first domain half corresponds to the first domain half of a first serine protease and the second domain half corresponds to the second domain half of a second serine protease, has improved properties and can be readily crystallized.

Abstract: A method of treatment using a compound of Formula I: 1

Abstract: Nucleoside-5′-triphosphates and phosphoramidites which carry a residue absorbing in the long wavelength region, preferably a carbocyanine group of the general formula (I), on the base portion or on the phosphorus atom in which R1 and R2 each denote hydrogen or together form a phenyl residue; R3 denotes hydrogen if linkage with the nucleotide is via the R4 position or it denotes a —NHCS— group if linkage with the nucleotide is via the R3 position; both R4 and R5, or R5, alone denote an alkylsulfonyl group with n being a number from 3 to 5 or R4 represents a —NHCS— group with n being a number from 3 to 8, as well as the use of the compounds to label, detect and sequence nucleic acids.

Abstract: The combination of two mechanisms of detection in a single device yields a method which allows the simple quantification of analyte determinations. Suitable formats and reagent kits are suggested.

Abstract: The present invention discloses a matrix formulation containing carvedilol.

Abstract: Magnetic particles with an outer glass surface being essentially poreless or having pores of a diameter of less then 10 nm as well as ferromagnetic particles with a glass surface are preferentially useful for the isolation of biological material from samples. They provide a quick and reliable purification.

Abstract: The present invention discloses a matrix formulation containing carvedilol.

Abstract: A method of treating amyloid diseases by administering a compound of Formula I: wherein: R7-R13 are independently —H or —OH; and A is H, —OH, or a moiety of Formula II:  wherein: R1 is hydrogen, lower alkanoyl of up to 6 carbon atoms or aroyl selected from benzoyl and naphthoyl; R2 is hydrogen, lower alkyl of up to 6 carbon atoms or arylalkyl selected from benzyl, phenylethyl and phenylpropyl; R3 is hydrogen or lower alkyl of up to 6 carbon atoms; R4 is hydrogen or lower alkyl of up to 6 carbon atoms, or when X is oxygen, R4 together with R5 can represent —CH2—O—; X is a valency bond, —CH2, oxygen or sulfur; Ar is selected from phenyl, naphthyl, indanyl and tetrahydronaphthyl; R5 and R6 are individually selected from hydrogen, fluorine, chlorine, bromine, hydroxyl, lower alkyl of up to 6 carbon atoms, a —CONH2— group, lower alkoxy of up to 6 carbon atoms, benzyloxy, lower alkylthio of up to 6 carbon atoms,

Abstract: Low coherence interferometer apparatus for investigation of a sample (15), in particular for multi-dimensional imaging, having an interferometer configuration (2) comprising a low coherence light source, a probe head (9) having a light exit opening (16) for irradiating light into the sample, an optical coupler, a reference reflector and a detector (13). The optical paths between the elements of the interferometer configuration (2) form interferometer arms. The optical coupler and the reference arm of the interferometer configuration (2) are integrated into a common optical chip (28). In addition to the reference reflector (11), the reference arm comprises a deflection reflector (33) formed on an end surface (35) of the optical chip (28) in such a manner that the reference light is cross-coupled between a first light guide (10a) forming a first portion of the reference arm (10) and a second light guide (10b) forming a second portion of the reference arm (10).

Abstract: A method of treatment using a compound of Formula I: 1

Abstract: The present invention concerns new conjugates, processes for their production as well as the use of these conjugates as antigens in immunological detection methods or for DNA diagnostics.

Abstract: The invention concerns a homogeneous immunoassay based on agglutination using an Fab′-biotin material and agglutinatable particles which carry streptavidin or avidin. The invention also concerns the Fab′-biotin which is bound or linked via linkage groups to a label compound which can electrochemiluminescence and the particles having avidin or streptavidin on their surface are magnetic.

Abstract: An aqueous protein solution buffered with a potassium phosphate buffer, in which the ratio of potassium ions to sodium ions in the solution is at least 10:1, is resistant to the formation of protein aggregates and particles under conditions of freezing, thawing, lyophilization, and reconstitution.

Abstract: Discussed are therapeutic approaches to the treatment of thrombolic conditions. The therapies use thrombolytically active proteins which inhibit reocclusion in the subject. The proteins are administered in two or more boli.

Abstract: In order to extend the measuring range and to reduce the Hook effect in an immunological method of determination of an antigen based on the principle of a sandwich assay it is preferable to use a method which is characterized in that the labelled detection molecule is an oligomer of a binding molecule selected from antibody or/and antibody fragment.

Abstract: Image recording system for the evaluation of analytical test elements with a holding unit (8) into which the test elements are placed or onto which they are placed as well as a lens system (5) which records an image of the test elements on a CCD chip (3) and an evaluation unit that evaluates the image on the CCD chip or displays it on a monitor. The image recording system enables numerous test elements of different sizes to be evaluated at different wavelengths without requiring focussing by the user. The lens system used for this is a reducing optical system with an aperture on the side of the image of at least 0.7 and a distance between the CCD chip and the nearest lens of the lens system of less than 15 mm. In addition the distance between the nearest lens of the lens system and the CCD chip is kept constant to at least 10 &mgr;m in order to ensure an adequate sharpness. A compensator is described for keeping this distance constant.

Abstract: A chimeric serine protease whose protease domain is composeD. of two domain halves (half-sides) with a &bgr;-folded sheet structure, wherein the first domain half corresponds to the first domain half of a first serine protease and the second domain half corresponds to the second domain half of a second serine protease, has improved properties and can be readily crystallized.

Abstract: A chimeric serine protease whose protease domain is composed of two domain halves (half-sides) with a .beta.-folded sheet structure, wherein the first domain half corresponds to the first domain half of a first serine protease and the second domain half corresponds to the second domain half of a second serine protease, has improved properties and can be readily crystallized.

Abstract: A peptide according to the present invention is not more than 40 amino acids long and contains a sequence which is at least 6 amino acids long from the amino acid partial sequence between the amino acids 144 and 183 of human .alpha.1-microglobulin or/and a sequence which is at least 6 amino acids long from the amino acid partial sequence between the amino acids 1 and 20 of human .alpha.1-microglobulin.An antibody according to the present invention is capable of specific binding to a peptide according to the present invention as well as to human .alpha.1-microglobulin.In order to determine human .alpha.1-microglobulin in a sample liquid by an immunoassay, the sample liquid is brought into contact simultaneously or sequentially with defined amounts of the components antibody and peptide whereby one of the components is labelled and the determination is carried out by means of this label.